{
    "clinical_study": {
        "@rank": "31835", 
        "arm_group": [
            {
                "arm_group_label": "Arm 1", 
                "arm_group_type": "Experimental", 
                "description": "MenB+OMV NZ"
            }, 
            {
                "arm_group_label": "Arm 2", 
                "arm_group_type": "Active Comparator", 
                "description": "MenACWY-CRM and placebo"
            }
        ], 
        "brief_summary": {
            "textblock": "Assess the immunogenicity and safety of two doses of Novartis Meningococcal B recombinant\n      vaccine administered one month apart (0, 1 month schedule) in Korean adolescents aged\n      between 11-17 years."
        }, 
        "brief_title": "Safety and Immunogenicity Study of Two Doses of Novartis Meningococcal B Recombinant Vaccine in Adolescents Aged 11-17 Years", 
        "completion_date": {
            "#text": "April 2014", 
            "@type": "Actual"
        }, 
        "condition": "Meningococcal Disease", 
        "condition_browse": {
            "mesh_term": "Meningococcal Infections"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Adolescents 11-17 years of age inclusive who have given their written assent and\n             whose parent or legal guardian has given written informed consent at the time of\n             enrollment\n\n          2. Available for all the visits scheduled in the study (i.e. not planning to leave the\n             area before the end of the study period)\n\n          3. In good health as determined by the outcome of medical history, physical examination\n             and clinical judgment of the investigator\n\n          4. With a negative urine pregnancy test (for female subjects only)\n\n        Exclusion Criteria:\n\n          1. History of any meningococcal vaccine administration\n\n          2. Current or previous, confirmed or suspected disease caused by N. meningitidis\n\n          3. Household contact with and/or intimate exposure to an individual with any laboratory\n             confirmed N. meningitidis infection within 60 days of enrollment;\n\n          4. Pregnancy or nursing (breastfeeding) mothers\n\n          5. Female subjects who have not used or do not plan to use acceptable birth control\n             measures, for the 2 months duration of the study.\n\n          6. Any serious chronic or progressive disease\n\n          7. Family members and household members of research staff\n\n          8. Any condition which in the opinion of the investigator may interfere with the\n             evaluation of the study objectives\n\n          9. Significant acute or chronic infection within the previous 7 days or fever within 3\n             days prior to enrolment\n\n         10. Antibiotics within 6 days prior to enrollment\n\n         11. Known or suspected impairment/alteration of the immune system, immunosuppressive\n             therapy\n\n         12. Receipt of blood, blood products and/or plasma derivatives, or a parenteral\n             immunoglobulin preparation within the previous 90 days\n\n         13. History of severe allergic reactions after previous vaccinations or hypersensitivity\n             to any vaccine component\n\n         14. Receipt of or intent to immunize with any other vaccine(s) within 30 days prior and\n             throughout the study period\n\n         15. Participation in another clinical trial within the last 90 days or planned for during\n             study"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "17 Years", 
            "minimum_age": "11 Years"
        }, 
        "enrollment": {
            "#text": "264", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "October 25, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01973218", 
            "org_study_id": "V72_42", 
            "secondary_id": "20130090378"
        }, 
        "intervention": [
            {
                "arm_group_label": "Arm 1", 
                "description": "Intramuscular vaccination of 2 doses of 0.5 ml in the non-dominant arm", 
                "intervention_name": "Meningoccal B recombinat vaccine", 
                "intervention_type": "Biological"
            }, 
            {
                "arm_group_label": "Arm 2", 
                "description": "Intramuscular vaccination of 2 doses of  0.5 ml in the non-dominant arm", 
                "intervention_name": "Meningococcal ACWY-CRM conjugate vaccine and placebo", 
                "intervention_type": "Biological"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": "Meningitis, adolescents, Meningococcal B", 
        "lastchanged_date": "April 8, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Seo-gu", 
                        "country": "Korea, Republic of", 
                        "state": "Busan", 
                        "zip": "602-702"
                    }, 
                    "name": "06 Kosin University Gospel Hospital 34, amnam-dong"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Ansan-si", 
                        "country": "Korea, Republic of", 
                        "state": "Gyeonggi-do", 
                        "zip": "425-707"
                    }, 
                    "name": "05 YuKorea University Ansan Hospital 23, Jeokgeum-ro, Danwon-gu"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Yangsan-si", 
                        "country": "Korea, Republic of", 
                        "state": "Gyeongnam", 
                        "zip": "626-770"
                    }, 
                    "name": "04 Pusan National University Yangsan Hospital 20 Geumo-ro, Mulgeum-eup"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bundang-gu", 
                        "country": "Korea, Republic of", 
                        "state": "Seongnam", 
                        "zip": "463-707"
                    }, 
                    "name": "07 Seoul National University Bundang Hospital 82, Gumi-ro 173 Beon-gil"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Jongno-gu", 
                        "country": "Korea, Republic of", 
                        "state": "Seoul", 
                        "zip": "110-744,"
                    }, 
                    "name": "01 Seoul National University Hospital 101 Daehang-ro,"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Yangcheon-gu", 
                        "country": "Korea, Republic of", 
                        "state": "Seoul", 
                        "zip": "158-710"
                    }, 
                    "name": "03 Ewha Womans University Mokdong Hospital, Department of Pediatrics, 911-1 Mokdong"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Incheon", 
                        "country": "Korea, Republic of", 
                        "zip": "400-711"
                    }, 
                    "name": "02 Inha University Hospital 7-206, 3rd street, Shinheung-dong, Jung-gu"
                }
            }
        ], 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Phase 3, Randomized, Observer-blind, Multicenter Study to Evaluate the Immunogenicity and Safety of Novartis Meningococcal B Recombinant Vaccine in Healthy Subjects Aged 11 to 17 Years in Korea", 
        "overall_official": {
            "affiliation": "Novartis Vaccines", 
            "last_name": "Novartis Vaccines", 
            "role": "Study Chair"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Korea: Ministry of Food and Drug Safety", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "April 2014", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "description": "Assess the Safety and Immunogenicity of two doses of Novartis Meningococcal B recombinant vaccine in adolescents aged between 11-17 years", 
                "measure": "Immunogenicity: assess percentage of subjects with SBA titer higher than or equal to 1:4", 
                "safety_issue": "No", 
                "time_frame": "1 month after last vaccination (Day 61)"
            }, 
            {
                "measure": "Safety: assess percentage and numbers of subjects with local and systemic adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "Until Day 7 post-each vaccination"
            }, 
            {
                "measure": "Safety: SAEs, medically attended AEs and AEs leading to study withdrawal", 
                "safety_issue": "Yes", 
                "time_frame": "Until study end (Day 61)"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01973218"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Immunogenicity of two doses of Novartis Meningococcal B recombinant vaccine in adolescents aged between 11-17 years", 
                "measure": "Immunogenicity: SBA GMTs, GMRs and fourfold-rise", 
                "safety_issue": "No", 
                "time_frame": "Baseline (Day 1)  and 1 month after last vaccination (Day 61)"
            }, 
            {
                "measure": "Immunogenicity: ELISA GMCs and GMRs", 
                "safety_issue": "No", 
                "time_frame": "Baseline (Day 1)  and 1 month after last vaccination (Day 61)"
            }
        ], 
        "source": "Novartis", 
        "sponsors": {
            "collaborator": {
                "agency": "Novartis Vaccines", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Novartis", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "November 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}